La cadena de opciones muestra datos clave de las opciones de acciones de Nektar Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Nektar Therapeutics..

Nektar Therapeutics (NASDAQ:NKTR) Bolsa, Cadena de Opciones

Nektar Therapeutics

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR)&nbsp;conference, being held in Washington, D.C. from November 14-19, 2024.
NKTR-422 is a novel modified&nbsp;hematopoietic colony stimulating factor (CSF) protein engineered to selectively modulate resolution processes of inflammation by targeting the expansion, reprograming and activation of anti-inflammatory tissue resident macrophages.
Currently approved inflammatory disease therapies are not designed to achieve inflammation resolution or tissue repair, which are both required for remission.1 Nektar has identified a CSF-1R agonist with a differentiated pharmacokinetic (PK)/pharmacodynamic (PD) profile compared to the native CSF-1 cytokine. Reduced clearance enables sustained PD activity from a single dose, unlike historical multiple dose per day necessary regimens of recombinant human CSF-1 administration. This CSF-1R agonist, NKTR-422, demonstrated inflammation resolution and tissue repair markers induction in tissue resident macrophages without induction of monocytosis and enhanced the efficacy of inflammatory cytokine blockade in rodent models.

Biotech

News

General

NKTR

Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology  Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 18.18 percent. The company reported quarterly sales of $24.124 million which beat the analyst consensus estimate of $18.281 million by 31.96 percent. This is a 0.08 percent decrease over sales of $24.144 million the same period last year.

Earnings

Earnings Beats

Nektar Therapeutics Q3 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate, Sales $24.124M Beat $18.281M Estimate

– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 –
– Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation &nbsp;–
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ --&nbsp;Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.

Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically Significant Lymphocyte Recovery Compared To Historical Controls At Week 8

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), citing the company&#8217;s lead asset rezpegaldesleukin&#8217;s (REZPEG) differentiated mechanism of action.
The analyst writes that Alopecia areata (AA) is an inflammatory skin disorder where patients require lifelong use of JAK inhibitors. Thus, REZPEG&#8217;s Treg mechanism has the potential to not only restore immune privilege but also provide durable disease control and transform patient quality of life.
In August, Nektar Therapeutics said its former partner,&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), had presented &#8220;erroneous data&#8221; from two Phase 1b <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33603172/why-is-nektar-therapeutics-stock-surging-today" rel="noreferrer noopener">studies of Rezpeg</a>.
In April, Nektar Therapeutics announced a strategic plan to reprioritize assets and restructure costs.
Regarding clinical programs, Nektar will prioritize the development of Rezpeg, either in collaboration with current partner Eli Lilly or&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/04/31850290/analyst-says-nektar-therapeutics-rezpeg-prioritization-likely-to-spark-investor-que" rel="noreferrer noopener">on its own in the future</a>.&nbsp;
Piper analyst writes, &#8220;Thus, by selectively stimulating Tregs, we believe REZPEG is uniquely positioned to restore immune homeostasis and mitigate the pro-inflammatory cascade across diseases&#8230;&#8221;
&#8220;REZPEG is strongly positioned to restore immune privilege and transform SoC,&#8221; the analyst adds.
Piper maintains a high probability of success for 36-week Phase 2b REZOLVE-AA n=84 Alopecia areata (AA) patients, with topline data expected in the first half of 2025.
Piper initiates with an Overweight rating and a price target of $7, an <a target="_blank" href="https://www.benzinga.com/quote/NKTR/analyst-ratings" rel="noreferrer noopener">upside of over 400%</a>.
Price Action: NKTR stock is up 10.2% at $1.355 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41718169/eni-completes-1-billion-alaska-asset-sale-fast-tracks-portfolio-goal-details" target="_blank" rel="noreferrer noopener">Eni Completes $1 Billion Alaska Asset Sale, Fast-Tracks Portfolio Goal: Details</a></li>
</ul>

Analyst Color

Equities

Health Care

Price Target

Initiation

Analyst Ratings

Movers

Trading Ideas

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

WIIM

Nektar Therapeutics shares are trading higher after the company announced it will sell its commercial PEGylation reagent manufacturing business to Ampersand Capital Partners.

Asset Sales

Nektar Therapeutics To Sell Its Commercial PEGylation Reagent Manufacturing Business To Ampersand Capital Partners For $90M Total Consideration, Comprised Of $70M In Cash and $20M Equity Ownership In New Portfolio Company

<h3>Gainers</h3>
<ul>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock moved upwards by 4181.6% to $274.02 during Monday's pre-market session. The market value of their outstanding shares is at $79.8 billion. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 8.88% to $14.59. The company's market cap stands at $316.7 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 8.07% to $2.41. The market value of their outstanding shares is at $84.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock rose 5.0% to $1.26. The company's market cap stands at $24.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 4.87% to $1.29. The market value of their outstanding shares is at $237.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 14.9% to $0.37 during Monday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) stock declined by 13.02% to $23.4. The market value of their outstanding shares is at $3.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 7.64% to $0.06. The market value of their outstanding shares is at $3.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock declined by 6.7% to $2.51. The company's market cap stands at $2.8 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) stock declined by 5.23% to $1.45. The company's market cap stands at $61.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVRX

RAPT

RXRX

TGTX

THAR

VERO

VRCA

10 Health Care Stocks Moving In Monday's Pre-Market Session

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Overweight rating and announces Price Target of $7.

Piper Sandler Initiates Coverage On Nektar Therapeutics with Overweight Rating, Announces Price Target of $7

- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials -
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO).
 &nbsp;

Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes

- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials -

Nektar Publishes Results From Phase 1b StudiesPof RezpegaldesleukinIin Two Inflammatory Skin Diseases

– Relapse-free/progression-free survival for NKTR-255 plus CD19-22&nbsp;CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) –
– Eight of nine patients achieved complete remission, all without detectable MRD –
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ --&nbsp;Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in Blood, the peer-reviewed medical journal of the American Society of Hematology.
NKTR-255 is a novel IL-15 receptor agonist currently being studied in clinical trials in combination with cellular therapies and immune checkpoint inhibitors. NKTR-255 has shown in previous clinical studies that it can proliferate a range of immune cells and augment lymphocyte trafficking.1,2
The data published in Blood showed favorable efficacy with eight out of nine patients (89%) whom successfully received CAR19-22 followed by NKTR-255 achieving measurable residual disease (MRD) negative remission. The study further demonstrated that, at 12 months, relapse-free/progression-free survival for NKTR-255 in combination with the CD19-22 CAR-T cell therapy was double that of historical controls (67% vs 38%).

Nektar Announces Publication In Blood Of Phase 1 Data For Novel IL-15 Agonist NKTR-255 In Combination With Autologous CD19-22 CAR-T Cell Therapy In Patients With B-cell Acute Lymphoblastic Leukemia

BTIG analyst Robert Hazlett assumes Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announces Price Target of $4.

BTIG Assumes Nektar Therapeutics at Buy, Announces Price Target of $4

Nektar Therapeutics Announced Several Presentations For Rezpegaldesleukin At The 2024 European Academy Of Dermatology And Venereology Congress

Nektar Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktr#NASDAQ">NKTR</a>) incurred a loss per share of 25 cents in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 21 cents.
Excluding the impact of non-cash restructuring and impairment charges, the company reported an adjusted loss of 19 cents per share in the second quarter of 2024 compared with an adjusted loss of 18 cents per share in the year-ago quarter.
Total revenues were $23.5 million in the second quarter, up 14.6% year over year. Revenues beat the Zacks Consensus Estimate of $17 million.
<h3>Quarter in Detail</h3>
In the second quarter, product sales increased around 42.5% year over year to $6.6 million. Product sales beat our model estimate of $4.6 million.
Non-cash royalty revenues were $16.8 million, up around 6.1% from the year-ago quarter. Non-cash royalty revenues beat our model estimate of $14.8 million.
Research and development (R&amp;D) expenses were $29.7 million, almost flat year over year.
General and administrative (G&amp;A) expenses increased 14.5% year over year to $20.5 million.
Nektar&#39;s stock was down 4.9% in after-hours trading on Aug 8 in response to the mixed results.
Shares of Nektar have skyrocketed 114.1% year to date against the industry&#39;s decline of 5.2%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/73847.jpg?v=1471947569" /> 
Image Source: Zacks Investment Research
<h3>Pipeline Updates</h3>
Nektar&#39;s lead pipeline candidate is rezpegaldesleukin (rezpeg), which is being developed as a self-administered injection for several autoimmune and inflammatory diseases. NKTR regained full rights to rezpeg from Eli Lily (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) in April 2023 and took charge of its clinical development.
Rezpeg was earlier developed in collaboration with Lilly for several autoimmune indications.
Rezpeg is now a wholly owned asset of Nektar and the company owes no royalty payments to LLY.
A phase IIb study is ongoing in patients with moderate-to-severe atopic dermatitis, also called eczema. Initial data from this study is expected in the first half of 2025.
Another phase IIb study is investigating rezpeg for treating patients with severe-to-very severe alopecia areata in March 2024. Top-line data from this study is expected in mid-2025.
<div class="chart_embed">
<h3>Nektar Therapeutics Price, Consensus and EPS Surprise</h3>
<img alt="Nektar Therapeutics Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/41/1723208145.png" style="height:265px; width:574px" title="" />
Nektar Therapeutics price-consensus-eps-surprise-chart | Nektar Therapeutics Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Nektar currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exact Sciences Corporation&nbsp;and Entrada Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trda#NASDAQ">TRDA</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Exact Sciences&#39; 2024 loss per share have narrowed from $1.09 to $1.00. Loss per share estimates for 2025 have narrowed from 21 cents to 8 cents. Year to date, shares of EXAS have decreased 22.6%.
EXAS&#39; earnings beat estimates in three of the trailing four quarters while meeting the same on the remaining occasion, the average surprise being 56.19%.
In the past 60 days, estimates for Entrada Therapeutics&#39; 2024 loss per share have narrowed from 14 cents to 13 cents. Loss per share estimates for 2025 have narrowed from $3.44 to $3.21. Year to date, shares of TRDA have lost 4.3%.
TRDA&#39;s earnings beat estimates in two of the trailing four quarters while meeting the same on the remaining two occasions, the average surprise being 42.18%.
<a href="https://www.zacks.com/stock/news/2320141/nektar-s-nktr-q2-earnings-lag-estimates-revenues-top?cid=CS-BENZ-FT-analyst_blog|earnings_article-2320141">To read this article on Zacks.com click here.</a>

Earnings Misses

Penny Stocks

Small Cap

Markets

TRDA

Nektar's Q2 Earnings Lag Estimates, Revenues Top

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $23.489 million which beat the analyst consensus estimate of $17.545 million by 33.88 percent. This is a 14.59 percent increase over sales of $20.499 million the same period last year.

Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate

– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism –
– IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 -

Events

Nektar Therapeutics Presents First Preclinical Data On NKTR-0165 For Treatment Of Inflammatory Diseases At EULAR 2024

Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 73.97 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $21.639 million which beat the analyst consensus estimate of $15.342 million by 41.05 percent. This is a 0.21 percent increase over sales of $21.594 million the same period last year.

Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $21.639M Beat $15.342M Estimate

<h3>Gainers</h3>
<ul>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares increased by 14.9% to $0.85 during Tuesday's after-market session. The market value of their outstanding shares is at $421.4 million. The company's, Q1 earnings came out today. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares increased by 13.97% to $8.32. The market value of their outstanding shares is at $195.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 11.92% to $1.69. The market value of their outstanding shares is at $310.3 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 8.33% to $0.26. The company's market cap stands at $20.0 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) stock increased by 7.99% to $1.89. The company's market cap stands at $46.5 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock rose 7.84% to $0.65. The company's market cap stands at $78.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares declined by 34.1% to $7.34 during Tuesday's after-market session. The market value of their outstanding shares is at $454.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) shares fell 15.87% to $206.67. The company's market cap stands at $6.2 billion. As per the press release, Q1 earnings came out today. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock declined by 15.71% to $23.73. The market value of their outstanding shares is at $166.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares fell 14.93% to $1.14. The market value of their outstanding shares is at $5.1 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 12.51% to $0.35. The market value of their outstanding shares is at $19.3 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 8.28% to $1.22. The company's market cap stands at $13.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATPC

ATRA

BSGM

CLOV

Euda Health Holdings Limited - Ordinary Shares

EUDA

INGN

INSP

OGEN

PHGE

SMLR

TMCI

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) stock moved upwards by 14.19% to $8.61. The market value of their outstanding shares is at $9.2 million. </li>
<li>Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock increased by 9.93% to $109.0. The company's market cap stands at $10.8 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SHL Telemedicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) stock decreased by 10.0% to $5.0 during Tuesday's pre-market session. The company's market cap stands at $81.9 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock declined by 8.87% to $1.33. The market value of their outstanding shares is at $244.3 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares fell 8.17% to $0.51. The market value of their outstanding shares is at $13.7 million. </li>
<li>GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) shares declined by 7.81% to $82.0. The market value of their outstanding shares is at $37.4 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock fell 7.28% to $0.44. The market value of their outstanding shares is at $8.3 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares decreased by 7.15% to $1.82. The market value of their outstanding shares is at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

ATNF

BRTX

CYCC

GCTK

GEHC

SHLT

VCNX

VIRI

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Nektar (NKTR) Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase 2 st...

Nektar presents late-breaking results from Phase 2 Study of NKTR-255

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Nektar releases promising phase 2 results for NKTR-255 in lymphopenia

Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M

Reports Q3 revenue $24.1M, consensus $18.28M. Cash and investments in marketable securities on September 30, 2024 were $249M as compared to $329.4M...

Nektar reports Q3 EPS (18c), consensus (20c)

Nektar Therapeutics ( ($NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its investors...

Nektar Therapeutics Reports Stable Q3 Earnings for 2024

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The company's shar...

Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

Multiple Catalysts Ahead For Nektar Therapeutics

Nektar (NKTR) announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology, or ACR, confe...

Nektar presents preclinical data on NKTR-422 at ACR conference

ALKS

APLS

CRBP

DERM

ELAB

RPRX

TKPHF

VKTX

VRNA

Press Releases

Nektar Management to Present at Upcoming Investor Conferences

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Comments

Nektar Therapeutics

Nektar Therapeutics (NKTR) Opciones

Nektar Therapeutics (NASDAQ:NKTR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL